Lexaria Bioscience CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Lexaria Bioscience Corp. Director Christopher Bunka gifted 100,000 common shares back to the company's treasury.
NASDAQ
Lexaria Bioscience Corp. Director Christopher Bunka has increased his indirect beneficial ownership in the company through recent open market purchases of common shares.
NASDAQ
Lexaria Bioscience Director William McKechnie purchased 5,000 common shares, increasing his direct ownership and signaling confidence in the company.
NASDAQ
Form 4: Lexaria Bioscience Executive Reports Future-Dated Share Purchase and Extensive Option Holdings
Lexaria Bioscience Corp.'s President and CSO, John Martin Docherty, reported a future-dated purchase of 5,376 common shares and detailed his significant stock option holdings.
NASDAQ
Lexaria Bioscience Corp. Secretary Vanessa Carle purchased 750 common shares at $0.91 per share, increasing her direct ownership.
NASDAQ
Lexaria Bioscience Corp.'s CEO and Director, Richard Christopher, purchased 15,000 common shares at $0.9094 per share, increasing his direct beneficial ownership to 65,000 shares.
NASDAQ
Form 4: Lexaria Bioscience CEO Richard Christopher Reports Stock Option Grant and Disposal of Shares
Lexaria Bioscience Corp's CEO, Richard Christopher, reports the acquisition of stock options and disposal of common shares in a recent SEC filing.
NASDAQ
Director Christopher Bunka reports acquisition of stock options and restricted stock award in Lexaria Bioscience Corp.
NASDAQ
Vanessa Carle, Secretary of Lexaria Bioscience Corp., reports the acquisition of 15,000 stock options.
NASDAQ
Form 4: Lexaria Bioscience Corp. Director John Docherty Reports Acquisition of 150,000 Stock Options
John Docherty, President and Director of Lexaria Bioscience Corp., reports the acquisition of 150,000 stock options.
NASDAQ
Michael Shankman, CFO of Lexaria Bioscience Corp., reports the acquisition of 50,000 stock options with an exercise price of $1.04.
NASDAQ
Director Baljinder Bhullar reports a transaction involving Lexaria Bioscience Corp. shares and stock options.
NASDAQ
Director Nicholas Baxter reports the disposition of 11,000 common shares and acquisition of 11,000 stock options in Lexaria Bioscience Corp.
NASDAQ
Director Albert L. Reese Jr. reports acquiring 11,000 stock options in Lexaria Bioscience Corp.
NASDAQ
William McKechnie, a director of Lexaria Bioscience Corp., reports the acquisition of 11,000 stock options.
NASDAQ
Lexaria Bioscience director Christopher Bunka acquired 100,000 common shares through a restricted stock award on January 7, 2025.
NASDAQ
Lexaria Bioscience's CEO, Richard Christopher, has acquired shares and has options that vest over time.
NASDAQ
Director Catherine Turkel reports the disposition and acquisition of Lexaria Bioscience Corp. common shares and holdings of stock options.
NASDAQ
Vanessa Carle, Secretary of Lexaria Bioscience Corp., reports the sale of 2,567 common shares on July 31, 2024.
NASDAQ
Director Albert Reese Jr. reports acquisition of 12,000 stock options in Lexaria Bioscience Corp.
NASDAQ
Director Catherine C. Turkel reports a transaction involving Lexaria Bioscience Corp. common shares and stock options.
NASDAQ
Director Nicholas W. Baxter reports a transaction involving Lexaria Bioscience Corp. common shares and stock options.
NASDAQ
William McKechnie, a director of Lexaria Bioscience Corp., reports the acquisition of 12,000 stock options and the disposal of 13,191 common shares.
NASDAQ
Vanessa Carle, Secretary of Lexaria Bioscience Corp., exercised stock options to acquire 2,500 common shares at $1.15 each on May 14, 2024.
NASDAQ
Vanessa Carle, Secretary of Lexaria Bioscience Corp., reports acquisition of stock options.
NASDAQ
Catherine C. Turkel, a director of Lexaria Bioscience Corp., acquired 5,000 stock options on April 26, 2024.
NASDAQ
Director Nicholas Baxter reports acquisition of 5,000 stock options in Lexaria Bioscience Corp.
NASDAQ
William Edward McKechnie, a director of Lexaria Bioscience Corp., reports the acquisition of 5,000 stock options.
NASDAQ
Director Albert L. Reese Jr. reports acquiring 5,000 stock options in Lexaria Bioscience Corp.
NASDAQ
Christopher Bunka, CEO of Lexaria Bioscience Corp., reports the acquisition of stock options and adjustments to previously held options and shares.